In an alternative approach (depicted as model II), an extended multivariate analysis for patients receiving anthracycline-based induction therapy including age (< 60 vs. ≥60 years), WBC, primary/ secondary AML, risk profile according NCCN, karyotype, FLT3-ITD mutation status, NPM1 mutation status, CEBPA mutation status, and CD318 expression was performed. The gene discussed is FLT3; the disease is acute myeloid leukemia.